TherapeuticsMD (TXMD) – Press Releases
-
TherapeuticsMD Announces Full Year 2023 Financial Results
-
TherapeuticsMD Announces Third Quarter 2023 Financial Results
-
TherapeuticsMD Announces Second Quarter 2023 Financial Results
-
TherapeuticsMD Announces First Quarter 2023 Financial Results
-
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
-
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
-
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
-
TherapeuticsMD Announces Third Quarter 2022 Financial Results
-
TherapeuticsMD Announces Additional $7 Million Private Placement
-
TherapeuticsMD Announces $7 Million Private Placement
-
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
-
TherapeuticsMD Announces Second Quarter 2022 Financial Results
-
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
-
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
-
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
-
TherapeuticsMD Announces Expiration of Tender Offer
-
EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer
-
EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD
-
THERAPEUTICSMD ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of TXMD and Encourages Investors to Contact the Firm
-
TXMD Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Acquisition of TherapeuticsMD by EW Healthcare Partners
-
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
-
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
-
TherapeuticsMD Announces First Quarter 2022 Financial Results
-
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
-
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
-
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
-
TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx
-
TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022
-
Karen L. Ling joins Galderma’s Advisory Committee
-
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
-
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
-
TherapeuticsMD Announces Third Quarter 2021 Financial Results
-
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
-
TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
-
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
-
Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*
-
Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month
-
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector
-
TherapeuticsMD Announces Appointment of Hugh O’Dowd as President
-
TherapeuticsMD Announces Second Quarter 2021 Financial Results
-
TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
-
TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA
-
The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award
-
TherapeuticsMD Announces First Quarter 2021 Financial Results
-
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting
-
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021
-
TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium
-
EU & UK Conclude Decentralised Procedure Approval for Bijuva® (Estradiol & Progesterone) Capsules for Hormone Replacement Therapy
-
TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results
-
TherapeuticsMD Announces Participation in Upcoming Investor Conferences
Back to TXMD Stock Lookup